ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Company Data

Name ZyVersa Therapeutics, Inc. - Common Stock

Company ZyVersa Therapeutics, Inc.

Symbol ZVSA

Website https://www.zyversa.com

Primary Exchange

NASDAQ

ISIN US98987D2018

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Stephen C. Glover

Country United States of America

Currency USD

Employees 0,0 T

Address 2200 N. Commerce Parkway, 33326 Weston

IPO Date 2022-02-11

ID Changes

Date	From	To
13.12.2022	LSPR	ZVSA

Ticker Symbols

Name	Symbol
NASDAQ	ZVSA

More Shares

Investors who hold ZyVersa Therapeutics, Inc. - Common Stock also have the following shares in their portfolio:

COREM PPTY GROUP PREF. Share

MITSUBISHI EL. CORP Share

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog